Company news
Echoiq Limited (ASX:EIQ) news
Echoiq Limited news releases on 6ix. Latest, Sep 6, 2024: Echo IQ Raises $7.1 million
Press releases — page 2
Echo IQ Raises $7.1 million
September 6, 2024
Groundbreaking study results for Heart Failure AI solution
September 3, 2024
Strategic Integration Partnership Agreement with ScImage Inc
July 4, 2024
Validation of EIQ AI at Leading Scientific Conference
June 5, 2024
Investor Presentation
May 22, 2024
Echo IQ Commences New Heart Failure Clinical Study Using AI
May 20, 2024
US FDA Application Lodged
May 6, 2024
Quarterly Report
April 30, 2024
Appendix 4C Cash Flow Report
April 30, 2024
Management Update
April 1, 2024
Completion of US Reader Study
March 27, 2024
Receipt of Research & Development Tax Incentive
March 7, 2024
Appendix 4D 31 December 2023
February 28, 2024
RSH: Cardiovascular AI platform integrated into RPM program
January 24, 2024
EIQ Licenses Software to Respiri - Remote Patient Mon.
January 24, 2024
EIQ Appoints Kimber Rothwell as CEO
January 15, 2024
Business Progress Update
December 13, 2023
Ord Minnett Healthcare Forum
October 29, 2023
Quarterly Activities Report
October 24, 2023
EIQ Investor Presentation updated
October 15, 2023
Paid Pilot with Australias Largest Cardiology Provider
August 28, 2023
Significant Expansion of EchoSolv Solutions Suite
August 20, 2023
Echo IQ Advances Global Regulatory Compliance Strategy
August 1, 2023
LAUNCH OF NEW ECHOSOLV SOLUTION FOR MITRAL REGURGITATION
July 18, 2023
ECHO IQ SECURES MAIDEN AUSTRALIAN HOSPITAL SALE OF ECHOSOLV
June 21, 2023
US Cardiovascular Facilities Access EchoSolv via Studycast
June 12, 2023
Echo IQ Delivers on Commercialisation
May 8, 2023
HYD: Hydrix signs agreement to sell EIQ's EchoSolv platform
May 1, 2023
Echo IQ Expands Commercial Footprint
May 1, 2023
Quarterly Activities/Appendix 4C Cash Flow Report
April 28, 2023
Flagship Clinical Trial Results At St Vincent Hospitals
April 19, 2023
Appendix 4D 31 December 2022
February 28, 2023
Amendment to Quarterly Report
February 1, 2023
Quarterly Activities/Appendix 4C Cash Flow Report - Dec
January 24, 2023
Positive Interim Results From Clinical Trial at St Vincents
December 14, 2022
Echo IQ Launches EchoSolv for Immediate Distribution
December 6, 2022
Echo IQ Announces Positive Results From US Clinical Study
November 30, 2022
Amendment to Appendix 4C
November 11, 2022
Quarterly Activities/Appendix 4C Cash Flow Report - Sept
October 28, 2022
Reinstatement to Official Quotation
October 12, 2022
Echo IQ Selected for HeartX Accelerator & Funding
October 11, 2022
Suspension from Official Quotation
October 6, 2022
New Research Presented at Leading Cardiology Conference
August 30, 2022
New Clinical Study with World-Leading US Teaching Hospital
July 26, 2022
Updated Appendix 4C Quarterly Cash Flow Report
July 19, 2022
Quarterly Activities/Appendix 4C Cash Flow Report - June
July 18, 2022
Presentation of Research Findings Behind Echo IQ Algorithm
July 6, 2022
Sale of Prometheus Information Pty. Limited
May 8, 2022
Formation of Scientific Advisory Board
April 25, 2022
Quarterly Activities/Appendix 4C Cash Flow Report - March
April 12, 2022